trending Market Intelligence /marketintelligence/en/news-insights/trending/t0alawhizcvyblst1vjdpw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Karyopharm Therapeutics elects director

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Karyopharm Therapeutics elects director

Newton, Mass.-based biotechnology company Karyopharm Therapeutics Inc. elected F. Carsten Thiel as a Class II director.

Thiel's term will expire at the company's 2021 annual meeting of stockholders.

Karyopharm's board increased the number of directors comprising the board to eight from seven and increased the number of Class II directors to two in connection with Thiel's appointment.